Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Burgstaller · SciRah

Researcher profile · Semantic Scholar

S. Burgstaller

Share profile

S. Burgstaller — researcher profile on SciRah

h-index: 25
Works: 95
Citations: 2,132

Most-cited papers

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
H. Gisslinger, Oleh Zagrijtschuk, V. Buxhofer-Ausch, J. Thaler +15 more
2015Blood192 citations Open access
Semantic Scholar
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
M. Dávid, N. Cross, S. Burgstaller, A. Chase +20 more
2007Blood173 citations Open access
Semantic Scholar
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
U. Jäger, M. Fridrik, M. Zeitlinger, D. Heintel +12 more
2012Haematologica110 citations Open access
Semantic Scholar
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
L. Pleyer, S. Burgstaller, M. Girschikofsky, W. Linkesch +16 more
2014Annals of Hematology100 citations Open access
Semantic Scholar
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
U. Jaeger, M. Trněný, Helen Melzer, M. Praxmarer +18 more
2015Haematologica84 citations Open access
Semantic Scholar
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
M. Steurer, M. Montillo, L. Scarfò, F. Mauro +15 more
2019Haematologica81 citations Open access
Semantic Scholar
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study f
M. Fridrik, U. Jaeger, A. Petzer, W. Willenbacher +8 more
2016European Journal of Cancer76 citations
Semantic Scholar
Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis.
C. Heibl, V. Trommet, S. Burgstaller, B. Mayrbaeurl +5 more
2010European Journal of Cancer Care75 citations
Semantic Scholar
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia
N. Cross, Yvette Hoade, W. Tapper, Gonzalo Carreño-Tarragona +32 more
2018Leukemia74 citations Open access
Semantic Scholar
p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor β in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder
F. Grand, S. Burgstaller, T. Kühr, E. J. Baxter +4 more
2004Cancer Research74 citations Open access
Semantic Scholar
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.
L. Pleyer, U. Germing, W. Sperr, W. Linkesch +16 more
2014Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis69 citations Open access
Semantic Scholar
Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
L. Pleyer, R. Stauder, S. Burgstaller, M. Schreder +14 more
2013Journal of Hematology & Oncology66 citations Open access
Semantic Scholar
Vascular endothelial growth factor in CSF
Günther Stockhammer, W. Poewe, S. Burgstaller, F. Deisenhammer +8 more
2000Neurology60 citations
Semantic Scholar
Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
G. Jeryczynski, J. Thiele, B. Gisslinger, A. Wölfler +14 more
2017American journal of hematology/oncology59 citations Open access
Semantic Scholar
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
H. Gisslinger, G. Jeryczynski, B. Gisslinger, A. Wölfler +10 more
2015Leukemia59 citations Open access
Semantic Scholar
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
F. Ramos, S. Thepot, L. Pleyer, L. Maurillo +15 more
2015Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis56 citations
Semantic Scholar
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
L. Pleyer, H. Döhner, H. Dombret, J. Seymour +23 more
2017International Journal of Molecular Sciences53 citations Open access
Semantic Scholar
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
Nicole C. C. Them, K. Bagienski, T. Berg, B. Gisslinger +17 more
2015American journal of hematology/oncology53 citations Open access
Semantic Scholar
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study
J. Riedl, F. Posch, G. Prager, W. Eisterer +19 more
2020Therapeutic Advances in Medical Oncology47 citations Open access
Semantic Scholar
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
R. Greil, P. Obrtlíková, L. Smolej, T. Kozák +31 more
2016The Lancet Haematology45 citations
Semantic Scholar
Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study
Beate Mayrbäurl, J. Giesinger, S. Burgstaller, G. Piringer +2 more
2016Supportive Care in Cancer41 citations
Semantic Scholar
The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab
B. Mayrbaeurl, M. Hinterreiter, S. Burgstaller, Martin Windpessl +1 more
2007Clinical Rheumatology41 citations
Semantic Scholar
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
L. Pleyer, S. Burgstaller, R. Stauder, M. Girschikofsky +18 more
2016Journal of Hematology & Oncology37 citations Open access
Semantic Scholar
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
A. Almeida, T. Prebet, R. Itzykson, F. Ramos +30 more
2017International Journal of Molecular Sciences32 citations Open access
Semantic Scholar
Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members
B. Mayrbaeurl, G. Keller, W. Schauer, S. Burgstaller +6 more
2010European Journal of Gastroenterology and Hepathology31 citations
Semantic Scholar
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)
J. Falantes, L. Pleyer, S. Thepot, A. Almeida +19 more
2018Leukemia and Lymphoma24 citations
Semantic Scholar
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
M. Hoeks, T. Bagguley, C. V. van Marrewijk, Alex Smith +201 more
2020Leukemia23 citations Open access
Semantic Scholar
Tuberin, p27 and mTOR in different cells
S. Burgstaller, Marsha Rich Rosner, C. Lindengrün, M. Hanneder +4 more
2009Amino Acids20 citations
Semantic Scholar
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
T. Kühr, S. Burgstaller, U. Apfelbeck, W. Linkesch +22 more
2003Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis20 citations
Semantic Scholar
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results
H. Gisslinger, V. Buxhofer-Ausch, J. Thaler, E. Forjan +16 more
2018Blood16 citations
Semantic Scholar
Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management
S. Burgstaller, P. Wiesinger, R. Stauder
2015Drugs & Aging16 citations
Semantic Scholar
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
G. Rinnerthaler, S. Gampenrieder, A. Petzer, S. Burgstaller +12 more
2018BMC Cancer12 citations Open access
Semantic Scholar
Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia
M. Steurer, M. Montillo, L. Scarfò, F. Mauro +11 more
201412 citations
Semantic Scholar
Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial
M. Fridrik, A. Petzer, F. Keil, W. Willenbacher +7 more
201112 citations
Semantic Scholar
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform
P. Valent, T. Lion, D. Wolf, C. Sillaber +10 more
2008Wiener Klinische Wochenschrift12 citations
Semantic Scholar
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients
G. Piringer, M. Fridrik, Alfred Fridrik, A. Leiherer +9 more
2018Supportive Care in Cancer11 citations
Semantic Scholar
BCR-ABL-negative chronic myeloid leukemia
S. Burgstaller, A. Reiter, N. Cross
2007Current Hematologic Malignancy Reports11 citations
Semantic Scholar
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study
H. Gisslinger, V. Buxhofer-Ausch, J. Thaler, E. Schloegl +14 more
201310 citations
Semantic Scholar
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
T. Sliwa, C. Beham-Schmid, S. Burgstaller, V. Buxhofer-Ausch +9 more
2017Wiener Klinische Wochenschrift9 citations
Semantic Scholar
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1
S. Burgstaller, R. Stauder, Thomas Kuehr, A. Lang +7 more
2018Leukemia and Lymphoma8 citations
Semantic Scholar
Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent
S. Burgstaller, S. Wimmer, B. Mayrbaeurl, W. Hoebling +1 more
2011Blood Cancer Journal8 citations Open access
Semantic Scholar
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
A. Egle, T. Melchardt, P. Obrtlíková, L. Smolej +33 more
2019Cancer Medicine7 citations Open access
Semantic Scholar
Chemotherapy line-associated differences in quality of life in patients with advanced cancer
Beate Mayrbäurl, L. Wintner, J. Giesinger, T. Himmelfreundpointner +3 more
2012Supportive Care in Cancer7 citations
Semantic Scholar
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial
H. Gisslinger, V. Buxhofer-Ausch, Juri Hodisch, A. Radinoff +18 more
2019British Journal of Haematology6 citations Open access
Semantic Scholar
Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data
L. Pleyer, S. Burgstaller, R. Stauder, M. Girschikofsky +18 more
20156 citations
Semantic Scholar
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
L. Pleyer, S. Burgstaller, R. Stauder, M. Girschikofsky +19 more
20146 citations
Semantic Scholar
The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study.
J. Riedl, Florian Posch, G. Prager, W. Eisterer +18 more
2019Annals of Oncology5 citations Open access
Semantic Scholar
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.
L. de Swart, Alex Smith, D. Haase, P. Fenaux +25 more
2018Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis5 citations Open access
Semantic Scholar
Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.
M. Windpessl, S. Burgstaller, Andreas Kronbichler, H. Pieringer +4 more
2018Transplantation Proceedings5 citations
Semantic Scholar
Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3)
Theodora Malli, M. Rammer, Sabrina Haslinger, J. Burghofer +7 more
2018Molecular Cytogenetics5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Greil×25
Invite
R. Greil — researcher profile on SciRah
J. Thaler×21
Invite
J. Thaler — researcher profile on SciRah
A. Lang×15
Invite
A. Lang — researcher profile on SciRah
R. Stauder×14
Invite
R. Stauder — researcher profile on SciRah

×12

Invite

L. Pleyer — researcher profile on SciRah

Invite

J. Andel — researcher profile on SciRah

Invite

A. Petzer — researcher profile on SciRah

M. Girschikofsky×9

Invite

M. Girschikofsky — researcher profile on SciRah

H. Gisslinger×8

Invite

H. Gisslinger — researcher profile on SciRah

V. Buxhofer-Ausch×8

Invite

V. Buxhofer-Ausch — researcher profile on SciRah

T. Melchardt×8

Invite

T. Melchardt — researcher profile on SciRah

Invite

D. Geissler — researcher profile on SciRah